Search

Displaying results 5511 - 5520 of 10000 in total
  1. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing. … PSN9301 is an oral small molecule inhibitor of Dipeptidyl Peptidase IV (DP-IV), being developed for the treatment of type 2 diabetes.

  2. Drug

    Nickel sulfate

    go.drugbank.com/drugs/DB14180
    Approved

    Nickel sulfate is used in allergenic testing.

    Mixtures: Multivitamins and Minerals Tablets, Milltrium Senior Vitamin and Mineral Supplement
  3. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. … It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.

  4. Drug

    SLV319

    go.drugbank.com/drugs/DB05077
    Experimental

    It is developed for the treatment of obesity and other metabolic disorders. … SLV319 belongs to a novel class of agents called CB1 antagonists, which work by blocking the cannabinoid type 1 (CB1) receptor.

    Categories: Cannabinoids and similars
  5. Drug

    CLBS12

    go.drugbank.com/drugs/DB18192
    Investigational

    CLBS12 is a GCSF-mobilized autologous cell therapy derived from CD34+ cells being investigated for the treatment of Buerger’s disease.

  6. Drug

    Monensin

    go.drugbank.com/drugs/DB11430
    ExperimentalVet approved

    Monensin is a polyether isolated from _Streptomyces cinnamonensis_ that presents antibiotic properties. It is widely used in ruminant animal feeds.

  7. Drug

    Aranidipine

    go.drugbank.com/drugs/DB09229
    Experimental

    [A31895] It was developed by Maruko Seiyaku, introduced by Taiho and launched in Japan in 1997.[T88] … Aranidipine is a novel dihydropyridine derivative that gives rise to two active metabolites (M-1α and M-1β) that exhibit hypotensive activity.

  8. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppression in models of acquired and genetic epilepsy with high CNS tolerability. … Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007.

  9. Drug

    Poa compressa pollen

    go.drugbank.com/drugs/DB10713
    Approved

    Poa compressa pollen is the pollen of the Poa compressa plant. Poa compressa pollen is mainly used in allergenic testing.

    Mixtures: Mixture of Standardized and Non-Standardized Inland Grasses, Mixture of Twenty-Two Standardized and Non-Standardized Grasses
  10. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

    Categories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and Proteins